The early GO decision in CAPTIVATE de-risks the CIDP program and supports upcoming Phase 3 initiation in gMG. With multiple near-term catalysts (MMN data in 2H'26, gMG trial start, DNTH212 data), the stock may re-rate on continued clinical execution. Monitor Part B guidance for CAPTIVATE by YE'26.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 9 $79.23entry
- T+1 · 8mo ago +9.71%α +9.89% · $86.92
- T+5 · 8mo ago −1.55%α −0.20% · $78.00
- T+20 · 7mo ago +8.80%α +11.60% · $86.20
- T+60 · 6mo ago +2.95%α −9.03% · $81.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP, based on achieving 20 confirmed responders in the interim analysis. The company has $514.4 million in cash, providing a runway into 2028, despite a widening net loss driven by increased R&D spending. Top-line data from multiple late-stage trials are expected in 2026–2028.
Key Financial Metrics
Key Facts
- Achieved early GO decision in Phase 3 CAPTIVATE trial for CIDP based on 20 confirmed responders with less than 40 participants completing Part A.
- Phase 3 trial in gMG expected to initiate mid-2026 with top-line results in 2H'28.
- Phase 2 MoMeNtum trial in MMN on track for top-line results in 2H'26.
- Phase 1 data for DNTH212 in healthy volunteers expected in 2H'26.
- Cash position of $514.4 million as of December 31, 2025, sufficient to fund operations into 2028.
- R&D expenses increased to $145.6 million in 2025 from $83.1 million in 2024, primarily due to clinical development and headcount growth.
- Net loss for 2025 was $162.3 million ($4.20 per share), up from $85.0 million ($2.55 per share) in 2024.
Financial Impact
Increased R&D spend by $62.5 million YoY; net loss nearly doubled to $162.3 million. Cash runway extended to 2028 despite higher burn.
Risk Factors
- Interim data from open-label Part A of CAPTIVATE is not randomized or controlled; final results may differ.
- No revenue from product sales; reliant on capital markets for future funding beyond 2028.
- Increased stock-based compensation contributing to higher G&A and R&D expenses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251709 |
Track record
23 reports on DNTH
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers